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Clinical heterogeneity and phenotype/
genotype findings in 5 families withGYG1
deficiency
ABSTRACT
Objective: To describe the variability of muscle symptoms in patients carrying mutations in the
GYG1 gene, encoding glycogenin-1, an enzyme involved in the biosynthesis of glycogen, and to
discuss genotype-phenotype relations.
Methods: We describe 9 patients from 5 families in whom muscle biopsies showed vacuoles with
an abnormal accumulation of glycogen in muscle fibers, partially a-amylase resistant suggesting
polyglucosan bodies. The patients had either progressive early-onset limb-girdle weakness or
late-onset distal or scapuloperoneal muscle affection as shown by muscle imaging. No clear
definite cardiac disease was found. Histologic and protein analysis investigations were performed
on muscle.
Results: Genetic analyses by direct or exome sequencing of the GYG1 gene revealed 6 different
GYG1 mutations. Four of the mutations were novel. They were compound heterozygous in 3
families and homozygous in 2. Protein analysis revealed either the absence of glycogenin-1 or
reduced glycogenin-1 expression with impaired glucosylation.
Conclusions: Our report extends the genetic and clinical spectrum of glycogenin-1–related
myopathies to include scapuloperoneal and distal affection with glycogen accumulation. Neurol
Genet 2017;3:e208; doi: 10.1212/NXG.0000000000000208
GLOSSARY
FSHD 5 facioscapulohumeral dystrophy; mRNA 5 messenger RNA; PAS 5 periodic acid–Schiff.
Mutations in genes involved in the muscular glycogen metabolism cause glycogen storage myo-
pathies and cardiomyopathies.1,2 Defects in enzymes that control muscle glycogen breakdown
are more common than diseases involved in glycogen synthesis. Glycogenin is a glycosyltransfer-
ase that catalyzes the formation of an 8–12 glucose molecule chain at its tyrosine 195 residue.3
Two types of glycogenin have been identified in humans: glyocogenin-1 and glycogenin-2
encoded by GYG1 and GYG2 genes, respectively.4,5 Glycogenin-1 (37 kDa) is expressed pref-
erentially in skeletal muscle and to a lesser extent in the liver, whereas glycogenin-2 (66 kDa) is
abundant in cardiac muscle and the liver but sparse in the pancreas and absent in skeletal muscle.
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Table Summary of the clinical and imaging features of the 9 patients
Patient
Whole phenotype/
symptoms of onset/
age, y
First clinical assessment
Disease course
at last assessment
Muscle
imaging
procedure
(no. of
assessments)
GYG1
mutations
Muscle biopsy:
muscle/age (y)/striking
pathologic features
Age, y/affected
muscles in UL
Age, y/affected
muscles in LL
First CPK
level (UI/
L)/EMG
ECG/
echocardiography
Pulmonary
functional
tests
A-1 (M) Scapuloperoneal/
running and climbing
stair difficulties, calf
and thigh cramps, and
knee drop/28–29
32/asymmetric
scapular weakness
atrophy (right Del and
SSp) and no scapular
winging
32/distal weakness (TA,
PL, and EDL) . proximal
weakness (GMe) and
stepping and waddling
gait
1,509/
myopathic
Nl/Nl Nl at 42 y
old, mild
FVC
decrease
(by 20%)
since 49 y
old
Del, BH, ECR, ECU,
and GMa weakness,
no UL elevation since
48 y old, used
a walking frame since
49 y old, and outside
wheelchair use since
50 y old
CT (3) and
WB-MRI (1)
(c.646C.T)1
(c.14313G.C)
First biopsy: Del/33/
vacuolar myopathy
containing PAS-positive
inclusions, fascicular
atrophy, mild necrosis, and
endomysial fibrosis; EM:
presence of normally
branched glycogen and no
fibrillary forms
Second biopsy: Del/36/
vacuolar myopathy
containing PAS-positive
inclusions and partially
a-amylase resistant; EM:
coexistence of normal
granular glycogen with
abnormal filamentous
glycogen and abnormal
dilated mitochondria
Third biopsy: ECR/48/
vacuolar myopathy
containing PAS-positive
inclusions, only 1 fiber was
a-amylase resistant
B-1 (M) Proximal/muscle
fatigability at running
without myalgia/16–
17
27/forearm muscle
hypertrophy, mild
scapular winging, and
no weakness
27/pelvifemoral
weakness (Ps, GMa, Adds
. GMe, and Ham), thigh
and gluteal atrophy, calf
hypertrophy, and
waddling gait
700–
1,100/
myopathic
Nl/Nl Nl Del, SSp, SSc, and IS
mild weakness at 28 y
old
CT (1) and
WB-MRI (1)
(c.14313G.C)1
(c.14313G.C)
Del/26/vacuolar myopathy
containing a-amylase–
resistant PAS-positive in-
clusions; EM: polyglucosan
bodies
B-2 (M) Proximal/muscle
fatigability at running
without myalgia/15
27/mild scapular
winging and no
weakness
27/pelvifemoral
weakness (GMe . Ps and
Ham), thigh and gluteal
atrophy, calf
hypertrophy, and
waddling gait
1,016/ND Nl/Nl Nl Del, SSp, SSc, and IS
mild weakness at 28 y
old
WB-MRI (1) (c.14313 G.C)1
(c.14313 G.C)
ND
B-3 (M) Asymptomatic/no
symptoms
23/no muscle weakness
and atrophy or
hypertrophy
23/no muscle weakness
and atrophy or
hypertrophy
Nl/ND ND/ND ND but no
respiratory
symptoms
ND CT (1) (c.14313 G.C)1
(c.14313G.C)
ND
C-1 (F) Distal/right then left
stepping gait/47–49
58/distal weakness (ED,
EDM, ECR, and ECU),
hand atrophy
(interosseus, thenar,
and hypothenar
muscles)
58/distal weakness (TA),
lower leg atrophy, and
stepping gait
Nl/
myopathic
AVB-II at 58 y old,
overt coronary
artery disease
since 70 y old
requiring stenting,
acetylsalicylic acid
and atorvastatin
Nl, OSAS at
70 y old
requiring
NnIV
PL and EDL weakness
at 73 y old
WB-MRI (1)
and MRI (3)
(c.14313 G.C)1
(c.996_1005del10)
First biopsy: TA/51/
vacuolar myopathy
Continued
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Table Continued
Patient
Whole phenotype/
symptoms of onset/
age, y
First clinical assessment
Disease course
at last assessment
Muscle
imaging
procedure
(no. of
assessments)
GYG1
mutations
Muscle biopsy:
muscle/age (y)/striking
pathologic features
Age, y/affected
muscles in UL
Age, y/affected
muscles in LL
First CPK
level (UI/
L)/EMG
ECG/
echocardiography
Pulmonary
functional
tests
Second biopsy: ECR/59/
vacuolar myopathy,
subsarcolemmal PAS-
positive material, type I
fiber predominance, mild
necrosis, and moderate
endomysial fibrosis; EM:
glycogen accumulation and
abnormal mitochondria
C-2 (M) Distal/left stepping
gait/72 (but older
difficulties in starting
efforts during
gymnastics, better
after 1 minute of
effort or alleviated by
taking sugar)
72/distal weakness (ED
and EDM), atrophy (ED,
EDM, right Tr, and right
Pec)
72/distal weakness (TA,
PL, and EDL) more than
pelvifemoral weakness
(GMa, GMe, Ps, and
hamstrings), thigh and
lower leg atrophy,
Achilles contractures,
and stepping gait
Nl/
myopathic
Nl Nl Difficulties in index
finger extension (left
then right) and
inability to stand from
squatting position at
77 y old
CT (1) and
WB-MRI (1)
(c.14313G.C)1
(c.996_1005del10)
First biopsy: TA/74/
advanced fibrofatty
degeneration and
myofibrillar myopathy
Second biopsy: Del/77/
vacuolar myopathy
containing a-amylase–
resistant PAS-positive
inclusions
C-3 (F) Distal/ankle twists,
frequent falls,
difficulties in climbing
stairs and getting up
from squatting, and
UL weakness/79
81/no weakness or
atrophy and left UL
elevation limitation
(musculotendinous cuff
surgery)
81/distal weakness (TA,
PL, and EDL) .
pelvifemoral weakness
(GMa, GMe, Ps, and Quad)
and inability to walk on
heels and tiptoes
ND/ND Myocardial
infarction at 76 y
old requiring
stenting
Nl Shortness of breath
on exertion
ND (c.14313G.C)1
(c.996_1005del10)
ND
D-1 (F) Proximal/problems in
climbing stairs/50
76/asymmetric
appearance, upper right
limbs more affected
than left, marked
atrophy of biceps
brachii on the right (2/
5), mild on the left (4/5),
and clear facial muscle
weakness
76/asymmetric
appearance and right LLs
more affected than the
left
252/
myopathic
Nl/Nl Nl Cannot walk without
support,
hyperlordotic,
waddling gait, and
uses rollator
WB-MRI (1) (c.166G.C)1
(c.472delA)
Vastus lateralis/76/
abnormal glycogen
accumulation (polyglucosan
bodies)
E-1 (F) Proximal/slower in
running and cycling
compared with her
peers/teen
45/pronounced anterior
thigh compartment
atrophy, hip flexion,
abduction, and
adduction and knee
extension weakness to
4 on MRC
Normal muscle strength 183/
myopathic
ND/ND ND Hyperlordotic and
walk without help
MRI (1) (c.487delG)1
(c.487delG)
Vastus lateralis/45/
myopathic with evidence of
abnormal glycogen
accumulation (polyglucosan
bodies)
Abbreviations: Add 5 thigh adductor; AVB 5 atrioventricular block; BH 5 biceps humeri; CPK 5 creatine phosphokinase; Del 5 deltoid; ECR 5 extensor carpi radialis; ECU 5 extensor carpi ulnaris; ED 5 extensor
digitorum; EDL5 extensor digitorum longus; EDM5 extensor digiti minimi; EM 5 electronic microscopy; FVC5 forced vital capacity; GMa5 gluteus maximus; GMe5 gluteus medius; Ham5 hamstring muscle; IS5
infraspinatus; LL 5 lower limb; MRC 5 Medical Research Council Scale for muscle power; ND 5 not done; Nl 5 normal; NnIV 5 nocturnal noninvasive ventilation; OSAS 5 obstructive sleep apnea syndrome; PAS 5
periodic acid–Schiff; Pec 5 pectoralis; PL 5 peroneus longus; Ps 5 psoas; Quad 5 quadriceps; SSc 5 subscapularis; SSp 5 supraspinatus; TA 5 tibialis anterior; Tr 5 trapezius; UL 5 upper limb; WB-MRI 5 whole-
body MRI.
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In the past 6 years, 20 patients of various
ethnic backgrounds have been reported with
glycogen storage myopathy due to GYG1 gene
mutations (GSDXV, OMIM #613507).6–12
Patients with GSDXV carry mutations leading
to inactivation of the autoglucosylation of
glycogenin-1 or impairment of glycogenin-1
interaction with glycogen synthase.6–8,12,13 In
reported cases of glycogenin deficiency, skele-
tal muscle involvement was always that of
a limb-girdle myopathy, accompanied in some
instances by an additional distal involve-
ment.6–13 Cardiomyopathy in patients with
GSDXV is rare,6,14 but mutations in the
GYG1 gene can be observed with no skeletal
muscle signs.14
We report here a detailed clinical and mus-
cle imaging assessment as well as protein and
genetic features of 9 patients with GSDXV.
Remarkably, the clinical spectrum uncovers
not only the previously reported proximal
myopathy but also new muscle patterns, thus
extending the clinical conditions due to
GYG1 gene mutations.
METHODS Five men and 4 women from 5 families originat-
ing from France (families A, B, and C) and Denmark (families
D and E) were included in this study (table and figure 1). Clin-
ical, histologic, and muscle imaging data were taken from the
patients’ medical records. Patient B-1 was reported as patient
P1 in a previous publication.7 During their follow-up, muscle
imaging was performed in all patients, except patient C-3: muscle
CT in 4 patients, muscle MRI in 2, and whole-body MRI in 6
(figure e-1, links.lww.com/NXG/A13).
Standard protocol approvals, registrations, and patients
consents. Written informed consent was obtained from all pa-
tients before muscle biopsies and DNA collection.
Muscle pathology analyses. At least 1 muscle biopsy was
performed in 6 patients (3 in A-1, 2 in C-2, and 1 in B-1,
C-1, D-1, and E-1) in deltoid in 4 patients, extensor carpi radi-
alis in 2, tibialis anterior in 2, and vastus lateralis in 2. Morpho-
logic and histochemical analyses of fresh-frozen muscle tissue
were performed by standard techniques, including periodic
acid–Schiff (PAS) staining before and after digestion with
a-amylase15 (figure 2).
Molecular genetic analysis. After DNA extraction from
peripheral leukocytes, coding regions of GYG1 were sequenced
(DNA Blood Mini kit, Qiagen, Hilden, Germany) and compared
with the reference sequence (accession number NM_004130).
Total messenger RNAs (mRNAs) were extracted from a fresh
muscle biopsy of patient B-1 (RNA Mini kit, Qiagen, Hilden,
Germany) and amplified by reverse transcription PCR (Promega,
Fitchburg, WI). Exome sequencing was performed in family C at
the French National Centre for Genotyping and in family D at
the Broad Institute’s Genomics Platform. Pathogenic mutations
were confirmed by Sanger sequencing.
Western blot. Expression of glycogenin-1 in myoblast cell
culture from patient A-1 and frozen muscle tissue from patients
B-1, C-1, and C-2 were explored by Western blot with
monoclonal antibodies against human glycogenin-1 N-terminal
1:500 (Abnova, Taipei, Taiwan) with or without a-amylase
treatment as previously described.7 For this purpose, samples
were treated with 10 mg/mL human a-amylase (Sigma-Aldrich,
St. Louis, MO) for 1 hour at 37°C to remove sugar residues of
the large glycogen molecules. Protein extracts were separated
onto 10% Mini-PROTEAN TGX precast gels (Bio-Rad Lab-
oratories, Marnes-la-Coquette, France). Immunoblots were
visualized by Immobilon Western Chemiluminescent HRP
Substrate (Millipore, Guyancourt, France) on a G-Box system
using GeneSnap software (Ozyme, Montigny-le-Bretonneux,
France). The glucosylated form of glycogenin-1 differs in size
by approximately 1 kDa compared with the a-amylase–treated
control.
RESULTS Clinical and muscle imaging features. Clini-
cally, the 9 patients in this study can be categorized
into 3 subgroups according to the pattern of muscle
affection: proximal, distal, and scapuloperoneal. The
proximal subgroup included patients B-1, B-2, and
E-1 who showed a teenage onset of pelvifemoral (B-
1, B-2, and E-1) and scapular weaknesses (B-1 and
B-2) (table and figure 1). This muscle affection was
confirmed by muscle imaging, showing partial and
symmetric fatty replacement of deltoid muscles in
upper limbs and a more advanced involvement of
gluteus magnus and medius, vastus lateralis and in-
termedius, adductor magnus, and biceps femoris
muscles in lower limbs (figures e-1E, e-1E9, e-1F,
e-1F9, e-1G, e-1G9, e-1O, and e-1O9, links.lww.
com/NXG/A13).
Conversely, patients C-1, C-2, and C-3 had a pre-
dominant distal myopathy pattern, manifesting late
in the fifth–eighth decade of life by asymmetric
stepping gait (table). Unfortunately, muscle imaging
was performed only in patient C-1 at disease onset
and showed a highly specific extensor tibialis anterior
muscle involvement (figure e-1I, links.lww.com/
NXG/A13). No earlier muscle imaging was available
for patients C-1 and C-2, and the oldest sister C-3
refused medical investigations. At more advanced
stages, the disease affected extensor digitorum and
medial gastrocnemius muscles (figures e-1I, e-1J,
e-1K9, e-1L, and e-1M9) but also progressed toward
proximal muscles (figures e-1J, e-1J9, e-1K, e-1K9,
e-1L, e-1M, and e-1M9).
Another unexpected presentation was observed
in patient A-1, who had a scapuloperoneal distribu-
tion in the first stages of the disease. For this patient,
muscle imaging was performed 4 times over the
course of 20 years, allowing us to precisely track
muscle involvement distribution and progression.
In the first 7–8 years of the disease onset, the pattern
was clearly peroneal in lower limbs, involving tibialis
anterior and extensor digitorum longus muscles and
4 Neurology: Genetics
to a lesser extent the soleus muscles (figure e-1A,
links.lww.com/NXG/A13) and scapular muscles in
upper limbs, mainly deltoid muscles in an asymmet-
ric pattern (figure e-1B). After 13–14 years of pro-
gression, the disease involved almost all calf muscles
and spread to the thighs and pelvic muscles, while at
this time, deltoids had become totally replaced by fat
(figure e-1C and e-1C9). In more advanced stages,
23–24 years after disease onset, almost all lower limb
muscles, anterior arm, and posterior forearm com-
partments were involved (figure e-1D and e-1D9).
Patient D-1 is peculiar, as she was diagnosed with
the disease at 50 years of age with difficulties climb-
ing stairs, suggesting a proximal lower limb
weakness at onset. Her assessment 26 years later
showed facial muscle weakness with a highly asym-
metric scapulohumeral and pelvifemoral myopa-
thies, thus resembling facioscapulohumeral
dystrophy (FSHD), which was excluded by genetic
testing. Muscle imaging showed a peculiar pattern
with scapulohumeral and a more diffuse lower limb
involvement. Unfortunately, there was no muscle
imaging performed at disease onset to better catego-
rize this patient pattern of myopathy. However, the
fact that distal parts of the upper and lower limbs
were more conserved than proximal parts suggests
that patient D-1 should be categorized within the
proximal subgroup of patients. Of note, asymmetric
Figure 1 Pedigrees of the 5 analysed families
The photographs of patients A-1, B-1, B-2, C-1, C-2, and D-1 are depicted under the corresponding symbols. * represents non tested subjects. White
squares and circles represent family members with no mutation in GYG1 gene. Black squares and circles represent homozygote or compound heterozygote
family members. Half black squares and circles represent heterozygote family members.
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limb involvement was found in 4 patients (A-1, C-1,
C-2, and D-1) involving deltoid muscles in 2 (A-1
and D-1) and distal lower limb muscles in 2 (C-1
and C-2). In addition, the creatine phosphokinase
(CPK) level was either normal in the oldest patients
(C-1, C-2, C-3, D-1, and E-1), while as high as 7
times above the upper reference level in the youngest
(A-1, B-1, and B-2).
All 9 patients reported here were also regularly as-
sessed for heart and respiratory involvement. Only 2 pa-
tients (patients C-1 and C-2) had cardiac abnormalities
in the context of coronary artery disease at age 58 and
76 years, respectively. Except for patient A-1, who
had mild restrictive respiratory syndrome, and patient
C-1 requiring night time nasal ventilation for obstruc-
tive sleep apnea syndrome since age 70 years, respiratory
assessments were unremarkable in all other patients.
Morphologic features. Almost all the 6 patients who
had a muscle biopsy performed showed PAS-
positive inclusions, partially resistant to a-amylase,
representing polyglucosan bodies (figure 2). Abnor-
mally structured glycogen, suggesting polyglucosan
bodies, was shown on electron microscopy in patients
A-1, B-1, C-2, D-1, and E-1 (data not shown).
Abnormal histologic findings, usually not associated
with GSDXV, were found in a few patients, such as
mild necrosis (patient C-1), moderate endomysial
fibrosis (patients C-1 and C-2), abnormal mito-
chondria accumulation (patients C-1), and extensive
fatty replacement and myofibrillar disarrangements
(patient C-3).
Molecular genetics. Results of molecular investigations
for tested family members are summarized in the
table. In patient A-1, we identified a new nonsense
mutation in exon 6 (c.646C.T, p.Arg216*) (in-
herited from his mother) in association with the pre-
viously reported7 splicing mutation in intron 2
(c.14313G.C, p.Asp3Glufs*4). In family B, the
Figure 2 Histological features in patients A-1, B-1, C-2, and D-1
For each patient, we included hematoxyline-eosine (HE) and periodic acid Schiff (PAS) staining before and after a-amylase
digestion (magnification x200 or x400).
6 Neurology: Genetics
same splicing mutation in intron 2 was found in
a homozygous state in twins (B-1 and B-2) and their
younger brother (B-3). Parents and sister were het-
erozygous for the mutation. Total mRNAs were ex-
tracted from a muscle biopsy from patient B-1,
allowing for the identification of 2 transcripts: the
previously reported in 4 families7—1 with exon 2
skipped and the normal one (figure 3A). Patient
E-1 carried a previously reported small out-of-frame
deletion (c.487delG, p.Asp163Thrfs*5).6
Exome sequencing of families C and D led to
the identification of 3 novel mutations in GYG1.
In family C, we identified 2 compound heterozy-
gous mutations: a small 10 bp out-of-frame dele-
tion in the last coding exon (NM_004130.3,
c.996_1005del10, p.Tyr332*) leading to a frame-
shift that creates a premature stop codon and may
produce a truncated protein and the previously re-
ported splicing mutation in intron 2
(c.14313G.C).7 The intron 2 mutation was
found in a heterozygous state in a nonaffected
brother and sister, while the 10-bp deletion was
found in a heterozygous state in another nonaf-
fected brother. In patient D-1, 2 compound het-
erozygous mutations (c.166G.C, p.Asp56His/
c.472delA, p.Asp159Thrfs*5) were identified.
Protein analysis. Expression of glycogenin-1 is shown
in figure 3. Under normal conditions, glucosylated
glycogenin-1 within glycogen particles cannot be
Figure 3 Effect of the mutation c.14313G>C
The top panel (A) is a proposed model explaining variable consequences of c.14313G.C mutation on RNA splicing with
production of two mRNA with or without exon 2. Reverse transcriptase PCR (RT-PCR) products using primers F (in exon 2)
and R (in exon 4) separated by electrophoresis shows the expected normal band at 290 bp in a patient carrying the
c.14313G.C mutation at homozygote state. Electropherogram represents the reverse RT-PCR product sequence using
R primer exhibiting exon 2-exon 3 junction. Western blot studies of glycogenin-1 myoblast cell culture (Panel B, patient A-1)
and fresh muscle biopsy (Panel C and D, Patients B-1, C-1 and C-2) without (-) or with (1) alpha-amylase treatment. For each
panel, the corresponding sex and age matched control tissue was used.
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detected unless the epitope is exposed after digestion
with a-amylase. In patient A-1 (figure 3B),
glycogenin-1 was absent before and after a-amylase
treatment, indicating that glycogenin-1 is not pro-
duced. In patient B-1 (figure 3B), glycogenin-1 was
not detected before a-amylase treatment, while it was
reduced after a-amylase treatment compared with
control, indicating that the expressed glycogenin-1
protein is still able to autoglucosylate. In patients
C-1 and C-2 (figure 3, C and D), glycogenin-1 was
detected before a-amylase treatment (2 bands with
a slight molecular weight difference) and was still
present (but lower molecular weight) at similar
amounts after a-amylase treatment, indicating pre-
served protein expression but impaired glucosylation.
DISCUSSION We report 9 patients who showed
unexpected clinical phenotypes and variable protein
consequences because of mutations in theGYG1 gene
of which 4 are novel.
Patient A-1 had an initial scapular and peroneal
pattern of muscle affection, which has not been
described previously in patients with GSDXV.
However, 1 patient described in the original descrip-
tion of the disease6 likely could have had the same
phenotype since he was described to have weakness
of shoulder abduction, elbow flexion and extension,
and foot dorsiflexion. Unfortunately, no muscle
imaging was performed in that patient to more accu-
rately classify the pattern of affection. In family C,
the disease started distally and evolved to the prox-
imal limb compartments. By contrast, the 9 pub-
lished patients showing distal involvement6–10 had
either an initial diffuse7,8 or a proximal6,7,9,10 pattern.
Only 1 published case7 may be reminiscent of family
C with primary distal involvement, although the
disease started late in lower limbs. On the other
hand, our 4 patients with proximal pattern are sim-
ilar to almost all the 20 cases reported so far.7–12
Indeed, these previously reported patients had a wide
range of age and symptoms at onset that generally
pointed toward limb-girdle weakness.7–12 In some
instances, symptoms of onset suggested exercise
intolerance,8,9,11,12 which was modest and was not
the predominant feature of the phenotype. CPK
levels were usually normal but were found mildly
to moderately elevated in 3 cases, reaching almost
1,100 IU/L in the youngest patient.7,9,11 The disease
course was progressive in all patients, and muscle
weakness was most disabling in the 7 oldest patients
(aged 57–82 years), as they were unable to raise arms
above their head and required aid for walking short
distances or permanent wheelchair use. Muscle
imaging was described only in 5 patients.8,10–12
Except for 1 patient with almost all muscles
involved,10 the 4 others had mainly affected scapular
and pelvifemoral girdle muscles similar to our pa-
tients B-1, B-2, and E-1 (figure e-1, links.lww.com/
NXG/A13). The open ring-like aspect of the right
soleus muscle observed in 1 patient8 was never
observed in our patients.
As for previously published patients,7,8,10,11 an
intriguing asymmetry was observed in at least 5 of
our patients manifesting as asymmetric weaker upper
limb elevation or scapular winging, associated in 1
patient with facial weakness leading initially to a clin-
ical diagnosis of FSHD. Thus, the presence of an
asymmetric muscle involvement in a patient with
glycogen storage myopathy should prompt GYG1
gene analysis.
Cardiac involvement has to be evaluated with
care. A patient previously reported6 developed ven-
tricular fibrillation since age 19 years, which
required implantable cardiac defibrillator. Among
the 18 other published cases, 11 had normal cardiac
assessments, while 7 had variable and inconclusive
cardiac abnormalities usually at advanced ages and
sometimes with clear coronary arteries or high
blood pressure diseases.7–12 These findings are sim-
ilar to those of our patients. Recently, a series of 3
patients with GYG1 mutation with severe cardiac
affections but with no skeletal muscular involve-
ment was published,14 suggesting that distinct phe-
notypes with cardiac or skeletal muscle
involvement exist, which could relate to the muta-
tion type.
All of our biopsied patients exhibited inclusions
containing PAS-positive material partially resistant
to a-amylase and abnormally structured glycogen
suggesting polyglucosan bodies. This is similar to
17 of the 20 previously reported patients, in whom
a major finding was the presence of inclusions in the
center and subsarcolemmal regions of up to 50% of
the fibers, containing a partially a-amylase–resistant
PAS-positive material. Inclusions surrounded by nor-
mal glycogen content were visualized in some fibers.
In other fibers, a depletion of normal glycogen was
observed around the inclusions. Similar to previously
reported cases,7,12 some of our patients showed occa-
sionally atypical features such as nemaline rods and
increased interstitial connective and fat tissues. It is
worthy to note that among those patients who had
abnormal PAS-positive inclusions, 2 had a first mus-
cle biopsy which was either normal10 or showed non-
specific myopathic features.9 Moreover, there are 2
patients who showed nonspecific myopathic changes
without inclusions or polyglucosan bodies.9,11 These
atypical features emphasize the benefit of repeating
muscle biopsy when the diagnosis has not formerly
been established.
The fact that mutations in 1 gene may lead to such
various clinical patterns is one of the intriguing results
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that arise from our study. From this point of view, the
mutation c.14313G.C seems to be particularly
demonstrative. Clinically, all the previously reported
11 patients carrying the homozygous c.14313G.C
mutation had a proximal pattern similar to the one
observed in the 2 affected patients from our family B.
However, there is a great heterogeneity at least in
terms of age at disease onset among individuals car-
rying this homozygous mutation. In fact, the 2 pa-
tients from family B had a teenage onset, while their
younger brother is still asymptomatic, suggesting
incomplete penetrance of this mutation. By contrast,
the age at onset of the disease in the 11 published
patients carrying this homozygous mutation ranged
from childhood to 55 years old. A muscle comple-
mentary DNA study from our patient B-1 revealed
not only the mRNA with exon 2 skipped as previ-
ously described7 but also the normal one. This new
finding can explain faint traces of protein observed in
patient B-1 myoblasts on Western blot and in the
different muscle biopsies of patients of family C, sug-
gesting variable levels of mRNA splicing in these tis-
sues. We speculate that the level of normal transcript
expression may modulate the deleterious effect of
glycogenin-1 deficiency and therefore the age at onset
and symptom intensity. Moreover, this balance
between the 2 forms seems variable among
individuals.
In our series, the c.14313G.C mutation was
also found in a compound heterozygous state com-
bined with the new nonsense c.646C.T mutation
(p.Arg216*) or the new out-of-frame 10 bp deletion
c.996_1005del10 (p.Tyr332*). The c.646C.T
mutation may result in a complete absence of protein
production through an mRNA nonsense-mediated
decay phenomenon. The total absence of
glycogenin-1 on Western blot found in myoblasts
from patient A-1 reinforces the notion of such a mech-
anism. On the other hand, a Western blot study of
muscle biopsies from patients C-1 and C-2 revealed
the presence of 2 unglucosylated glycogenin-1 bands
without a-amylase treatment, probably the normal
form and the shorter form related to p.Tyr332*. This
result is comparable with a Western blot finding from
previously reported patient 77 carrying the
c.14313G.C mutation and the nonsense
c.970C.T (p.Arg324*), which also showed 2 unglu-
cosylated glycogenin-1 bands without a-amylase
treatment. Based on this observation, we speculate
that this shorter protein had different deleterious ef-
fects on the normal one resulting from the
c.14313G.C mutation. We hypothesize that trun-
cated GYG1 protein impairs normal autoglucosyla-
tion of the normal form. Different phenotypes could
be explained by imbalance in the production of nor-
mal mRNA, mRNA with exon 2 skipped, and
truncated mRNA. The more this shorter protein is
abundant, the more distal the phenotype seems to be.
Clearly, these mutations need to be more deeply
investigated at mRNA, protein, and functional levels
to help us better understand their phenotypic
consequences.
Our findings demonstrate that GYG1 mutations
may lead to a wide spectrum of clinical phenotypes
including limb-girdle and scapuloperoneal muscle
weaknesses but also late-onset distal myopathy. This
study also highlighted the value of glycogenin-1 pro-
tein and mRNA studies to better understand the phe-
notype/genotype correlations in this group of
diseases.
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